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Results of a four years sweat test analysis for screening of Cystic 
Fibrosis in the Piedmont region of Italy 
M.P. Forneris 1, I. Baussano 1,I. Tardivo 1, A. Velj kovic 1, E. Bignamini  1 
~Paediatric CF Center; Piemonte am] l&IIe d'Aosta, A.O. O.LR.M S.Anna, Torino, 
Italy 
Purpose of this work is to check whether significant differences exist among sweat 
tests of children attending Oystic Fibrosis (CF) Centre at different step of CF 
neonatal screening, in the period from December 2000 to October 2CO4. 
137384 newboms were screened whit assay for immtmoreactive trypsinogen (IRT). 
2298 (1.7%) had IRT higher thma cut off and were submitted to genetic maalysis. 
265 of these have f inal ized the screening programme to sweat test. 40  (15.1%) were 
positive (chlorine > 40 meq/l) and 225 (84.9%) negative (chlorine < 40 meq/l). 
Chlorine concentration was determinate with sweat est (Gibson & Cook method for 
ionic chromatography). 
265 children submitted to sweat test were subdivided into 3 different groups 
depending on the 3 different screening's steps ha which they aucived at sweat test. 
First group consists of children with IRT < 80 ng/ml and 1 mutation; second group 
consists of subjects with a firts IRT > 80 ng/ml, without mutations and with second 
IRT higher thma 40 ng/ml mad third group consists of children with IRT > 80 mad 1 
mutation. 
Fol lowing table compares results of sweat ests (chlorine concentration expressvA 
as medium value) in the 3 different groups for positive and negative subjects. 
positive negative total 
1 ~up Total Number (%): 8 (7,8%) 95 (92,2%) 103 (38,9%) 
Chlorine concentration (medium value): 68,377 93,967 
2 ~x~up Total Number (%): 1 (1,1%) 87 (98,9%) 88 (33,9%) 
Chlorine concentration (mediunl value): 98,711 93,151 
3 ~x~up Total Number (%): 31 (41,9%) 43 (38,1%) 74 (97,9%) 
Chlorine concentration (medium value): 114,432 96,425 
total 40 225 265 
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Age appropriate reference intervals for sweat sodium and sweat 
chloride in the diagnosis of cystic fibrosis 
C. Bal l  6, M. Montgomery 1"~, A.W. Lyon 136, M.E. Lyon 1346 
iUniversity of Calgary, 2Departrnent of Pediatrics, 3Department of Pattu~logy am] 
Laboratory Medicine, ~Department of Ptu~rma~ology am] Therapeutics, ~Alberta 
ChiMren's Hospital, Cystic Fibrosis Clinic, 6Calgary Laboratory Services 
Aims:  To establish age appropriate r ference intervals for sweat sodium and sweat 
chloride concentrations measured by quantitative pilccarpine iont ophoresis (QPIT) 
at Alberta Children's Hospital. 
Methods: A retrospective chart review of consecutive patients with QPIT 
performed ha the years 1996 2(100 (n 1099) was undertaken. Alberta Children's 
Hospital is a centralized sweat testing center for southem Alberta, Canada. Patient 
demographics, sweat sodium concentration, sweat chloride concentration and 
definit ive diaguosis data were extracted from the charts. Sweat sodium was 
determined by f lame photometry (IL943) and sweat chloride was determined by 
chloridometer (Radiometer CMT 10). Age dependent reference intervals for sweat 
sodium and chlorides were determined parametrically (95% confidence interval). 
Results:  The population of 1099 patients tested included 29 patients with clinically 
confirmed cystic fbrosis that were removed from the dat aset prior to calculating the 
reference intervals. 
Sample Sweat Chloride Sweat Sodium 
Age Size Reference Interval Reference Interval 
0 363 days 242 3 90 mrnol/L 5 97 mrnol/L 
ly 5y 343 4 99 mrnol/L 6 36 mrnol/L 
>3y 173 6 56 mrnol/L 9 67 mrnol/L 
Conclusions: Age appropriate reference intervals for sweat sodium and sweat 
chloride are significantly distinct from the commonly used reference intervals. 
Future studies wi l l  evaluate the clinical impact of applying age specific reference 
intervals. 
504 
Neonatal screening's uSlity for early diagnosis of CysSc Fibrosis in 
the Piedmont region of Italy 
G. Restagno 1,A. Gomez 1, C. Mar i  1, M. Ferr aris 1, A.M. Sedita 1, I. Baussano ~, M.P. 
Forneris 2, I. Tardivd, A. Velj kovic 2, S. Pagliardini ~,E. Bignamini  2 
~Molecular ,Genetics Service, A.O. O.ZR.M S.Anna, Torino, Italy, 2paediatric CF 
Center, Pi emonte atul l&IIe d'Aosta, A.O. O.L R.M S.Anna, Totin G Italy, SNeonataI 
Screening Centtw, A.O. O.LR.M. S.Anna, Totin G Italy 
Purpose of this work is to colgir m the benefit of a four years neonatal screening's 
program for early diaguosis of Oy stic Fibrosis (CF) in the Piedmont regions of Italy, 
in the period from December 2 (~)  to October 2CO4. 
The neonatal screening program is a two step pr at c~ol which combines the assay for 
immunoreactive trypsinogen (IRT) with the analysis of 31 mutations in the CFTR 
gene using the OLA PCR SCS method irectly on the Gufllrie blood spot. 
In 47 month period, 137384 newboms were screened. The results of our screening 
strategy is: 2298 (1.7%) had IRT higher than cut off and were analysed with the 
PRC OLA. 26 newboms with 2 mutations in the CFFR gene were directly referred 
to the CF Centre. The sweat test was performed on 202 heterozygous infants: 17 
were diaguosed as CF. Between 43 newborns diagnosed as CF (IRT> cut off, sweat 
test positive), 26 presented two mutations, 16 one mutation and 1 no detectable 
mutations. The 17 patients who had none or only one mutation were analysed with 
DHPLC:12 patients carried two mutations and 3 patients only one mutation. 
Finally, 36.6% of patients are homozygotes (93.3% AF508, 6.7%Rl17H),  46.3% 
compound heterozygotes mad 9.8% heterozygotes. Incidence of CF is 
approximately 1/3195 (0.03%) and cmrier frequency 1/12 (8.0%). 
Four false negative patients were ascertained ( etection rate: 91.5%). 
Consequently, the screening programme permits an early and accurate diaguosis of 
CF, diminishing average t ime from 18 month, without neonatal screening, to 6 
week. 
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MULTI-CODE@ CFTR Gene Multi-Mutation Analysis on Luminex TM 
Microspheres 
B. Fercot 1, B. Mercier 1, J. Prudent 2, D. Marshal l  ~, M. P. Audr6zet 1, C. F6rec 1 
~Laboratoire de Gdndtique MoIdculaire, Brest, France, 2EraGen Bioscienees, 
Madison, Wisconsin 
Fifteen years after the characterisation of the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene, and the identification of over 1300 mutations, 
CF is now to become the first disease targeted for population wide genetic 
screening. 
MULTI  CODE® CFTR Gene Mul t i  Mutat ion Analysis  on Luminex  TM 
Microspheres i  a high throughput mult iplex genotyping of CFTR mutations. It has 
been developed to screen for the twenty f ive most common mutations 
recommended by The American College of Medical  Genetics (ACMG) and for four 
polymorphisms. 
The system begins with mult iplex PCR with coded primers and incorporation of a 
labelled AEGIS TM (An expanded Genetic Information System) triphosphate which 
generates a target specific signal. Each specific product is then captured at room 
temperature using an ERA CODE® system which allows mol~u lar  ecoguition 
with an ERA CODE sequence covalently fixed to a single microsphere. Automated 
flow cytometry with the Luminex l00  allows each micr osphere to be identified and 
tested for asscciated reporter signal. 
The Luminex technology allows up to 1(20 different beads in a single tube, each of 
them being identified by a specific red orange fluorescence. A normal or mutated 
al lele wi l l  be detected by a green fluorescence. 
The test is rapid (4 hours from the DNA to the result), is performed in a single tube 
from the PCR to the detection without any manipulation of the samples. Using 96 
wells microplates, it can be adapted to automation and allows large series to be 
performed. 
This test was evaluated on previously genotyped samples carrying the mutations 
and on 5(20 blood spots of newborns. This technique distinguishes between 
homozygotes mad heter ozygotes for all the mutations. The results were in agreement 
with data obtained using DHPLC or ARMS technology. 
